BSE: 544169 | NSE: | Medical Equipment/Supplies/Accessories | Small Cap
Past 10 year's financial track record analysis by Moneyworks4me indicates that Amkay Products Ltd is a average quality company.
The key valuation ratios of Amkay Products Ltd's currently when compared to its past seem to suggest it is in the Fair zone.
The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Amkay Products Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
| Mar'21 | Mar'22 | Mar'23 | Mar'24 | TTM | |
|---|---|---|---|---|---|
| ROCE % ⓘ | 71.9% | 29.3% | 24.7% | 28.8% | - |
| Value Creation Index ⓘ | 4.1 | 1.1 | 0.8 | 1.1 | - |
Growth Parameters ⓘGrowth Parameters Colour Code Guide ⓘ | |||||
| Sales ⓘ | 40.7 | 36.5 | 27.9 | 31.1 | 31 |
| Sales YoY Gr. | - | -10.3% | -23.7% | 11.5% | - |
| Adj EPS ⓘ | 5 | 2.3 | 2.4 | 4.1 | 3 |
| YoY Gr. | - | -53.6% | 3% | 73.5% | - |
| BVPS (₹) ⓘ | 7.5 | 9.8 | 12.2 | 15.7 | 26.1 |
| Adj Net Profit ⓘ | 3.2 | 1.5 | 1.5 | 2.6 | 3 |
| Cash Flow from Ops. ⓘ | 3.4 | -0.3 | 1 | -0.7 | - |
| Debt/CF from Ops. ⓘ | 0.4 | -17.3 | 4.8 | -7.8 | - |
CAGR Colour Code Guide ⓘ
| 9 Years | 5 Years | 3 Years | 1 Years | |||||
|---|---|---|---|---|---|---|---|---|
| Sales ⓘ | NA | NA | -8.6% | 11.5% | ||||
| Adj EPS ⓘ | NA | NA | -6.1% | 73.5% | ||||
| BVPSⓘ | NA | NA | 28.3% | 29.3% | ||||
| Share Price | - | - | - | - | ||||
Performance Ratio Colour Code Guide ⓘ
| Mar'21 | Mar'22 | Mar'23 | Mar'24 | TTM | |
|---|---|---|---|---|---|
| Return on Equity % ⓘ | 66.9 | 26.8 | 21.8 | 29.7 | 14.5 |
| Op. Profit Mgn % ⓘ | 11.4 | 7.4 | 11.4 | 10.7 | NAN |
| Net Profit Mgn % ⓘ | 7.8 | 4 | 5.4 | 8.5 | 8.5 |
| Debt to Equity ⓘ | 0.3 | 0.7 | 0.6 | 0.6 | - |
| Working Cap Days ⓘ | 0 | 78 | 114 | 121 | 0 |
| Cash Conv. Cycle ⓘ | 0 | -6 | 26 | 62 | 0 |
Debt to equity has declined versus last 3 years average to 0.55
Return on Equity has declined versus last 3 years average to 14.50%
Sales growth has been subdued in last 3 years -8.61%
Net Profit has been subdued in last 3 years -6.05%
Sales growth is not so good in last 4 quarters at 0.00%
| Standalone | Consolidated | |
|---|---|---|
| TTM EPS (₹) | 3 | - |
| TTM Sales (₹ Cr.) | 31.1 | - |
| BVPS (₹.) ⓘ | 26.1 | - |
| Reserves (₹ Cr.) ⓘ | 14 | - |
| P/BV ⓘ | 2.18 | - |
| PE ⓘ | 18.76 | - |
| From the Market | |
|---|---|
| 52 Week Low / High (₹) | 56.17 / 120.96 |
| All Time Low / High (₹) | 56.17 / 120.96 |
| Market Cap (₹ Cr.) | 49.3 |
| Equity (₹ Cr.) | 8.7 |
| Face Value (₹) | 10 |
| Industry PE ⓘ | 79 |
| Pledged * | 0.00 | 0.00 |
| PARTICULARS | Mar'21 | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|---|
| Sales | 40.70 | 36.50 | 27.86 | 31.07 |
| Operating Expenses ⓘ | 36.11 | 33.82 | 24.70 | 27.74 |
| Manufacturing Costs | 2.07 | 2.08 | 1.17 | 1.49 |
| Material Costs | 25.34 | 25.78 | 18.08 | 20.02 |
| Employee Cost | 5.23 | 4.58 | 4.29 | 4.51 |
| Other Costs ⓘ | 3.48 | 1.37 | 1.15 | 1.72 |
| Operating Profit ⓘ | 4.59 | 2.69 | 3.17 | 3.33 |
| Operating Profit Margin (%) | 11.3% | 7.4% | 11.4% | 10.7% |
| Other Income ⓘ | 0.08 | 0.29 | 0.39 | 1.25 |
| Interest ⓘ | 0.21 | 0.41 | 0.50 | 0.52 |
| Depreciation ⓘ | 0.28 | 0.54 | 0.71 | 0.56 |
| Exceptional Items ⓘ | 0 | 0 | 0 | 0 |
| Profit Before Tax ⓘ | 4.18 | 2.04 | 2.34 | 3.50 |
| Tax ⓘ | 1.05 | 0.57 | 0.81 | 0.87 |
| Profit After Tax | 3.13 | 1.47 | 1.53 | 2.63 |
| PAT Margin (%) | 7.7% | 4.0% | 5.5% | 8.5% |
| Adjusted EPS (₹) | 4.9 | 2.3 | 2.4 | 4.1 |
| Dividend Payout Ratio (%) | 0% | 0% | 0% | 0% |
| PARTICULARS | Mar'21 | Mar'22 | Mar'23 | Mar'24 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
Equity and Liabilities | ||||||||||
| Shareholders Fund | 4.74 | 6.21 | 7.74 | 10 | ||||||
| Share Capital ⓘ | 0.28 | 0.28 | 0.28 | 6.36 | ||||||
| Reserves ⓘ | 4.46 | 5.93 | 7.46 | 3.64 | ||||||
| Minority Interest | 0 | 0 | 0 | 0 | ||||||
| Debt | 1.37 | 4.32 | 4.37 | 5.01 | ||||||
| Long Term Debt | 1.35 | 3.47 | 3.35 | 1.28 | ||||||
| Short Term Debt | 0.02 | 0.85 | 1.02 | 3.74 | ||||||
| Trade Payables | 5.74 | 4.55 | 2.49 | 2.06 | ||||||
| Others Liabilities ⓘ | 1.79 | 0.49 | 1.02 | 0.66 | ||||||
| Total Liabilities ⓘ | 13.64 | 15.57 | 15.63 | 17.74 | ||||||
Fixed Assets | ||||||||||
| Gross Block | 6.01 | 8.16 | 8.15 | 8.90 | ||||||
| Accumulated Depreciation | 3.72 | 4.25 | 4.89 | 6.32 | ||||||
| Net Fixed Assetsⓘ | 2.30 | 3.91 | 3.26 | 2.58 | ||||||
| CWIP ⓘ | 0 | 0 | 0 | 0 | ||||||
| Investmentsⓘ | 3.52 | 2.79 | 3.62 | 3.23 | ||||||
| Inventories | 0.29 | 1.98 | 2.61 | 5.61 | ||||||
| Trade Receivables | 4.09 | 3.63 | 3.71 | 3.99 | ||||||
| Cash Equivalents | 0.92 | 0.20 | 0.05 | 0.11 | ||||||
| Others Assetsⓘ | 2.52 | 3.04 | 2.39 | 2.21 | ||||||
| Total Assets ⓘ | 13.64 | 15.57 | 15.63 | 17.74 | ||||||
| PARTICULARS | Mar'21 | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|---|
| Cash Flow From Operating Activity ⓘ | 3.38 | -0.25 | 0.98 | -0.70 |
| PBT ⓘ | 4.18 | 2.04 | 2.34 | 3.50 |
| Adjustment ⓘ | 0.35 | 0.77 | 0.76 | 0.07 |
| Changes in Working Capital ⓘ | -0.03 | -2.55 | -1.52 | -3.38 |
| Tax Paid ⓘ | -1.12 | -0.52 | -0.60 | -0.90 |
| Cash Flow From Investing Activity ⓘ | -1.98 | -3.07 | -1.39 | 0.47 |
| Capex | -1.20 | -2.15 | -0.02 | -0.73 |
| Net Investments | -0.40 | -1.26 | -1.57 | 0.39 |
| Others ⓘ | -0.38 | 0.34 | 0.21 | 0.82 |
| Cash Flow From Financing Activityⓘ | -0.65 | 2.59 | 0.26 | 0.29 |
| Net Proceeds from Shares ⓘ | 0 | 0 | 0 | 0 |
| Net Proceeds from Borrowing ⓘ | 0.10 | 2.12 | -0.12 | -2.07 |
| Interest Paid ⓘ | -0.14 | -0.38 | -0.45 | -0.47 |
| Dividend Paid ⓘ | 0 | 0 | 0 | 0 |
| Others ⓘ | -0.61 | 0.85 | 0.83 | 2.84 |
| Net Cash Flow ⓘ | 0.76 | -0.72 | -0.15 | 0.06 |
| PARTICULARS | Mar'21 | Mar'22 | Mar'23 | Mar'24 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Ratios | ||||||||||
| ROE (%) | 65.98 | 26.81 | 22 | 29.65 | ||||||
| ROCE (%) | 71.91 | 29.32 | 24.73 | 28.84 | ||||||
| Asset Turnover Ratio | 2.98 | 2.5 | 1.79 | 1.86 | ||||||
| PAT to CFO Conversion(x) | 1.08 | -0.17 | 0.64 | -0.27 | Working Capital Days | |||||
| Receivable Days | 37 | 39 | 48 | 45 | ||||||
| Inventory Days | 3 | 11 | 30 | 48 | ||||||
| Payable Days | 83 | 73 | 71 | 42 | ||||||
Amkay Products was originally incorporated as ‘Amkay Products Private Limited’ on October 25, 2007 under the provisions of the Companies Act, 1956 with the Registrar of Companies, Maharashtra, Mumbai. Subsequently, pursuant to Special Resolution passed by the Shareholders at the Extra Ordinary General Meeting, held on August 02, 2023, the Company was converted into a Public Limited Company and consequently the name of the Company was changed from ‘Amkay Products Private Limited’ to ‘Amkay Products Limited’ vide a fresh certificate of incorporation consequent upon conversion from private company to public company dated August 28, 2023 issued by the Registrar of Companies, Maharashtra, Mumbai.
It manufactures, assemble & market a comprehensive portfolio of medical devices, disposables and other Healthcare Products like Face Mask, Alcohol Swabs, Lancet Needles, Nebulizer, Pulse Oximeter, surgeon cap etc. used by healthcare centers, hospitals/clinics, nursing homes etc. widely spread across India. In addition, it is also engaged in branding and marketing of some of the products like Diapers, Plastic Gloves, Suction Machines etc. The company started its operations in year 2008 with manufacturing and supply of one product in a manufacturing unit taken on rent at Vasai in Mumbai. Gradually, more products were added to its portfolio & for further product expansion, over the period, it shifted to bigger manufacturing units from where it entered into branding & trading segment also along with manufacturing. The company’s product portfolio comprises of many product including Respiratory Disease Related Medical Devices, Surgical Disposables, Home Healthcare Products and Other Healthcare Products.
Its manufacturing facilities are equipped with requisite infrastructure including machineries, testing laboratory other handling equipment to facilitate smooth manufacturing process. Further, the company has accreditation with ISO 9001:2015 for quality management system from QRO Certification LLP. The company was founded in the year 2007 by one of its Promoters, Kashyap Pravin Mody, who has experience in the associated industry. Later, in 2011, Hemanshu Kantilal Batavia joined the company as Director who has an experience in the said industry. Its promoters are involved in the critical aspects of its business, including expansion, process and plant, finance, sales and marketing. Their understanding of the consumer difficulty, intuitive entrepreneurship and involvement in key aspects of its business has helped accelerate and drive its profitable growth.
Business area of the company
It manufactures, assemble & market a comprehensive portfolio of medical devices, disposables and other Healthcare Products like Face Mask, Alcohol Swabs, Lancet Needles, Nebulizer, Pulse Oximeter, surgeon cap etc. used by healthcare centers, hospitals/clinics, nursing homes etc. widely spread across India. In addition, it is also engaged in branding and marketing of some of the products like Diapers, Plastic Gloves, Suction Machines etc.
Products of the company
History and milestones
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Make an informed decision for Stocks
Invest using an intelligent system with powerful data-driven tools that help you identify opportunities and make informed buy-hold-sell decisions
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
Claim your FREE 15-day access to the most practical investing handbook.
Hurry, limited to the first 10 users today!
FREE Become a savvy and confident
stock investor.
Hurry, limited to the first 10 users today!
Download APP
